SERVIER

Servier launches Voradenig for brain cancer patients after 24-year treatment gap Servier introduced Voradenig for brain cancer patients in late 2023, representing the first new therapy approved for this indication since 1999. The treatment addresses a significant unmet medical need in oncology where patients have historically had limited therapeutic options.

Brain cancer presents unique challenges for pharmaceutical development due to the bloodbrain barrier, which prevents many compounds from reaching target tissues. This biological obstacle has limited treatment innovation and contributed to poor patient outcomes. Traditional brain cancer treatment has relied on surgery, radiation therapy and chemotherapy. These approaches often provide limited efficacy while causing significant side effects that impact patient quality of life.

An estimated

patients are treated with Servier’ s medicines every day

Late in 2024 the company launched the first new therapy for brain cancer patients in almost 24 years, representing validation of Servier’ s research and development capabilities in oncology. Successfully bringing a brain cancer treatment to market requires sustained investment in research, clinical development and regulatory expertise over multiple years.

Servier maintains growth trajectory through strategic technology partnerships Servier expects continued growth over the next 12 to 18 months, building on technology foundations established during its rapid US expansion. The company has evolved from a startup operation in shared workspace facilities to an established pharmaceutical organisation with dedicated facilities.

The transformation from 10 employees in a Boston conference room to more than 600 staff across two building floors demonstrates successful scaling of operations and technology infrastructure. This growth required systematic technology investments that could support increasing complexity.

Pharmaceutical technology landscapes continue evolving, particularly in AI applications for drug discovery and patient services. Companies, like Servier, that maintain strategic technology roadmaps can capitalise on emerging capabilities while avoiding costly implementation mistakes.

healthcare-digital. com 91